Description overdue on 22.01.2012

Hepatoprotectors . Mainly active substance acts ursodeoxycholic acid . The drug has a lipid-lowering, cholelitolitic, choleretic, hypocholesterolemic and weakly expressed immunomodulatory effects. The mechanism of action is based on the incorporation of the basic substance in the cell membrane of hepatocytes, obespetsichvaya protection from the damaging effects of bile salts. Ursofalk stimulates exocytosis It activates Ca2 + dependent alpha protease It reduces the concentration of toxic bile acids in cholestasis . By lowering the secretion, hepatic cholesterol synthesis system, inhibition of absorption in the intestinal lumen decreases saturation of bile with cholesterol. The drug stimulates bile formation, zhelchevyvedenie, increases the solubility of cholesterol in the bile, pancreatic and enhances gastric secretion, has hypoglycemic effect It increases activity lipase Decreases lithogenicity bile , Increases the amount of bile acids   in bile. Under the influence of the drug Ursofalk is a full or partial dissolution of gallstones containing cholesterol. Available in the form of a suspension of capsules.

Indications:

Ursofalk prescribed for uncomplicated cholelithiasis to dissolve the cholesterol-containing gallstones. The drug is used with active chronic hepatitis, chronic opistorhoze , Primary biliary cirrhosis , Toxic lesions of the liver system (alcohol, drug form), the primary sclerosing cholangitis , Parenteral cholestasis, biliary reflux gastritis, biliary reflux esophagitis, acute hepatitis, alcoholic gepatoze , Atresia of the intrahepatic bile ducts, nonalcoholic steatohepatitis , Liver pathology at cystic fibrosis , Biliary dyspeptic syndromes, congenital biliary atresia,   neonatal cholestasis . Ursofalk recommended for use for the prevention of liver disease while taking cytostatics, hormonal contraceptives, obesity.

Contraindications:

Ursofalk not indicated the presence of rentgenpolozhitelnyh gallstones, while bile-digestive fistula , Non-operation gallbladder, acute cholangitis, chronic hepatitis, decompensated cirrhosis, acute cholangitis, obstruction of the biliary tract , Renal and liver failure systems, inflammatory bowel disease, pancreatitis , Infection of the bile duct, bladder, empyema of the gallbladder . The drug is not used during breastfeeding, pregnancy.

Side effect:

Increased liver enzymes, constipation . alopecia , Back pain, dose-related diarrhea, nausea, dizziness, exacerbation of psoriasis, allergies, vomiting.

Mode of application:

Ursofalk taken before a meal, do not chew the capsule. If cholelithiasis drug take 1 time before going to bed, in the pathology of the liver - 2-5 capsules three times a day. In order to prevent re cholelithiasis Ursofalk taken twice daily with 300 mg. When biliary reflux esophagitis, biliary reflux gastritis: 250 mg at bedtime, therapy - up to six months.

Special instructions:

Successful treatment is achieved only when it comes to pure cholesterol content of stones, the size of which does not exceed 20 mm. During treatment requires regular monitoring of liver enzymes . Holetsistografii   necessary to carry out monthly during the first 3 months, then 1 time in 3 months. Efficacy was evaluated by the results of the ultrasound every 6 months. By achieving results, the dissolution of cholesterol stones need to continue taking the drug Ursofalk for 3 months.

Drug Interactions:

Estrogens , Lipid-lowering drugs (clofibrate), progestins, neomycin increase the saturation of bile with cholesterol, which adversely affects the solubility of cholesterol stones. Ion exchange resin ( kolestiramin ) And   antacids   reduce the effectiveness of the drug Ursofalk.